• 1
    Edlund C, Nord CE. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 (Suppl. S1): 418.
  • 2
    Orrhage K, Nord CE. Bifidobacteria and lactobacilli in human health. Drugs Exp Clin Res 2000; 26: 95111.
  • 3
    Rice LB. Emergence vancomycin-resistant enterococci. Emerg Infect Dis 2001; 7: 1837.
  • 4
    Reinke CM, Messick CR. Update on Clostridium difficile-induced colitis, Part 1. Am J Hosp Pharm 1994; 51: 177181.
  • 5
    D'Antonio D, Iacone A, Schioppa FS, Bonfini T, Romano F. Effect of the current antimicrobial therapeutic strategy on fungal colonization in patients with hematologic malignancies. Curr Microbiol 1996; 33: 11822.
  • 6
    Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 37582.
  • 7
    Salyers AA, Shoemaker NB. Resistance gene transfer in anaerobes: new insights, new problems. Clin Infect Dis 1996; 23 (Suppl. 1): 3643.
  • 8
    Fung-Tomc JC, Minassian B, Kolek B et al. Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000; 44: 33516.
  • 9
    Gales A, Sader H, Jones RN. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999). Antimicrob Agents Chemother, 2001; 45: 14636.
  • 10
    Takahata M, Mitsuyama J, Yamashiro Y et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999; 43: 107784.
  • 11
    Takahata M, Shimakura M, Hori R et al. In vitro and in vivo efficacies of T-3811ME: (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001; 45: 31215.
  • 12
    Sader HS, Jones RN, Gales AC et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American Medical Centers with a diagnosis of pneumonia: analysis of results from the SENTRY antimicrobial surveillance program (1997). Diagn Microbiol Infect Dis 1998; 32: 289301.
  • 13
    Jones RN, Croco MAT, Kugler KC, Pfaller MA, Beach ML. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997. Diagn Microbiol Infect Dis 2000; 37: 11525.
  • 14
    Biedenbach DJ, Jones RN. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagn Microbiol Infect Dis 2000; 36: 2559.
  • 15
    Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY antimicrobial surveillance program (1997). Antonie Van Leeuwenhoek 2000; 77: 14752.
  • 16
    Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 35264.
  • 17
    King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am Fam Physician 2000; 61: 27418.
  • 18
    Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58 (Suppl. 2): 6570.
  • 19
    Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 815.